Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) PT at $91.55
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) has been given an average rating of “Moderate Buy” by the ten research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month […]
More Stories
Cousins Properties (NYSE:CUZ) Stock Rating Lowered by StockNews.com
Cousins Properties (NYSE:CUZ – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a...
Mohawk Industries (NYSE:MHK) Upgraded at StockNews.com
Mohawk Industries (NYSE:MHK – Get Free Report) was upgraded by investment analysts at StockNews.com from a “hold” rating to a...
StockNews.com Upgrades Viavi Solutions (NASDAQ:VIAV) to “Buy”
Viavi Solutions (NASDAQ:VIAV – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy”...
Wishbone Gold (LON:WSBN) Stock Price Down 4.2% – Should You Sell?
Shares of Wishbone Gold Plc (LON:WSBN – Get Free Report) dropped 4.2% during trading on Thursday . The company traded...
Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Increased to Strong-Buy at StockNews.com
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was upgraded by stock analysts at StockNews.com from a “buy” rating to...
Shoe Zone (LON:SHOE) Stock Passes Below 50-Day Moving Average – Here’s What Happened
Shares of Shoe Zone plc (LON:SHOE – Get Free Report) crossed below its fifty day moving average during trading on...